The Ministry of Health allowed the trial of a vaccine from Biocad

The Ministry of HEALTH issued the St. Petersburg company Biocad (Biocad) permission to conduct clinical trials of its vaccine against CORONAVIRUS in RUSSIA, follows from the data of the state register of medicines.

The start date is Monday, July 26, they will last until December 2026. They will be held on the basis of two St. Petersburg medical organizations: the Yuninova research center and the X7 Clinical Research center, 360 people will take part in them. We are talking about the first and second phases of research.

The purpose of the study is "to evaluate the safety and immunogenicity of a recombinant vector viral vaccine based on AAV5-RBD-S for the prevention of coronavirus infection ( covid-19 )."

The agency also allowed in Russia clinical trials of a combination of AstraZeneca and Sputnik Light vaccines (they are designated by the codes AZD1222 and rAd26-S), follows from the registry. The first and second phase trials will last until March 2022, the drug will be studied on 150 patients. The studies will take place in five organizations in Moscow and St. Petersburg, their goal is “to study the safety and immunogenicity of a combination of drugs administered according to the “heterologous prime-boost” scheme.”